A paper utilizing our TCR Repertoire Analysis was published by Dr. Keisuke Ota, Department of Immunology, Yamaguchi University Graduate School of Medicine, who has investigated the therapeutic efficacy of next-generation CAR-T cells (7×19 CAR-T) that produce IL-7 and CCL19 against glioblastoma and pancreatic cancer, which are refractory cancers, using mouse models.
To confirm the cytotoxic activity and therapeutic efficacy of 7×19 CAR-T, they experimented two models using anti-EGFRvIII CAR-T generated from epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma and healthy donor PBMCs, and human epidermal growth factor receptor 2 (HER2)-positive pancreatic cancer organoids and in vitro and in vivo evaluation in models with anti-HER2 CAR-Ts generated from PBMCs of the same patients. The results by each experiment were induced the result in prolonged survival in mice. This study is the first to demonstrate the therapeutic efficacy of next-generation CAR-T in an autologous model using patient-derived tumor organoid and CAR-T generated from the same patient's PBMC, in which unwanted allogeneic immune responses are fully excluded.
We have performed a Repertoire Analysis using TCR α and β chains before (from PBMC creation) and after (from splenocytes) injection of 7×19 CAR-Ts sorted CAR-positive and negative T cells.

Cancer Research Communications
Therapeutic efficacy of IL-7/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer

To "Publications" page